title: Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma.
abstract: OBJECTIVE
  Because of the trade-off between the potentially negative quality-of-life (QoL) effects and uncertain favorable survival effect of neoadjuvant chemoradiotherapy (CRT) in patients with resectable esophageal cancer, we assessed heath-related QoL (HRQoL) for up to 1 year postoperatively in these patients treated with preoperative CRT with a non-platinum-based outpatient regimen followed by esophagectomy.
  
  
  METHODS
  Patients undergoing neoadjuvant paclitaxel and carboplatin therapy concurrent with radiotherapy followed by surgery completed standardized HRQoL questionnaires before and after CRT and at regular times up to 1 year postoperatively. We analyzed differences in generic Qol core questionnaire [QLQ-C30] and condition-specific (esophageal site-specific [OES-18]) HRQoL scores over time by using a linear mixed-effects model.
  
  
  RESULTS
  Mean scores of most HRQoL scales deteriorated significantly during neoadjuvant CRT. The largest deterioration was observed for physical and role-functioning scales. All except two symptom scores worsened significantly. Postoperatively, most mean HRQoL scores improved until recovery to baseline level. Speed of improvement varied. Average taste score returned to baseline 3 months postoperatively, whereas it took 1 year for the average role-functioning score to restore. The emotional-functioning score showed a different pattern; it was worst at baseline and increased over time during CRT and postoperatively. Dysphagia and pain scores worsened considerably during CRT, restored to baseline 3 months postoperatively, and were even significantly better 1 year postoperatively.
  
  
  CONCLUSIONS
  Preoperative CRT with paclitaxel and carboplatin for patients with resectable esophageal cancer had a considerable temporary negative effect on most aspects of HRQoL. Nonetheless, all HRQoL scores were restored or even improved 1 year postoperatively.
authors.affiliation: Department of Medical Oncology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands. e.vanmeerten@erasmusmc.nl
authors.forename: Esther
authors.initials: E
authors.lastname: van Meerten
authors.forename: Ate
authors.initials: A
authors.lastname: van der Gaast
authors.forename: Caspar W N
authors.initials: CW
authors.lastname: Looman
authors.forename: Hugo W G
authors.initials: HW
authors.lastname: Tilanus
authors.forename: Karin
authors.initials: K
authors.lastname: Muller
authors.forename: Marie-Louise
authors.initials: ML
authors.lastname: Essink-Bot
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016190:Carboplatin / Q000009:adverse effects; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D016629:Esophagectomy; D005260:Female; D006304:Health Status; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects* / Q000379:methods; D017239:Paclitaxel / Q000009:adverse effects; D011446:Prospective Studies; D011788:Quality of Life; D011878:Radiotherapy / Q000009:adverse effects; D020127:Recovery of Function
chemical_list: D016190:Carboplatin; D017239:Paclitaxel